Slagelse Hospital, Slagelse, Denmark; University of Southern Denmark, Odense, Denmark; Steno Diabetes Center, Gentofte, Denmark.
Slagelse Hospital, Slagelse, Denmark; University of Southern Denmark, Odense, Denmark.
Kidney Int. 2017 Apr;91(4):982-988. doi: 10.1016/j.kint.2016.11.023. Epub 2017 Feb 7.
In the present post hoc analyses we studied the impact of intensified, multifactorial treatment on renal outcomes in patients with type 2 diabetes and microalbuminuria enrolled in the Steno-2 Study. Outcome measures were progression to macroalbuminuria, decline in the glomerular filtration rate (GFR), and development of end stage renal disease (ESRD). In total, 160 patients with type 2 diabetes and microalbuminuria were recruited and assigned to conventional or intensified therapy targeting multiple risk factors. The mean duration of the intervention was 7.8 years after which all patients were offered intensified therapy over a total follow-up up to 21 years on albuminuria, GFR, ESRD and mortality. Progression to macroalbuminuria was significantly reduced in the intensive-therapy group with a hazard ratio of 0.51 [95% confidence interval 0.32, 0.84]. The decline in GFR was significantly different with 3.1 ml/min/year in the intensive-therapy group compared to 4.0 in the conventional-therapy group. Progression to ESRD trended towards a decreased hazard with an adjusted ratio in the intensive group of 0.36 [0.12, 1.05]. ESRD combined with death had a significantly reduced hazard ratio of 0.53 [0.35, 0.8]. Thus, intensified, multifactorial treatment slowed progression in nephropathy and renal function loss reducing the risk of ESRD.
在本事后分析中,我们研究了强化、多因素治疗对 2 型糖尿病和微量白蛋白尿患者的肾脏结局的影响,这些患者参加了 Steno-2 研究。结局测量指标为进展为大量白蛋白尿、肾小球滤过率(GFR)下降和终末期肾病(ESRD)的发展。总共招募了 160 名患有 2 型糖尿病和微量白蛋白尿的患者,并将其分配到常规或强化治疗组,针对多个危险因素进行治疗。干预的平均持续时间为 7.8 年,之后所有患者均接受强化治疗,在白蛋白尿、GFR、ESRD 和死亡率方面的总随访时间长达 21 年。强化治疗组的大量白蛋白尿进展显著减少,风险比为 0.51[95%置信区间 0.32,0.84]。强化治疗组的 GFR 下降明显不同,为 3.1ml/min/年,而常规治疗组为 4.0ml/min/年。进展为 ESRD 的风险呈下降趋势,强化治疗组的调整比值为 0.36[0.12,1.05]。ESRD 合并死亡的风险比显著降低,为 0.53[0.35,0.8]。因此,强化、多因素治疗减缓了肾病和肾功能丧失的进展,降低了 ESRD 的风险。